|
||||||
|
Datasets with this analysis |
 This table only shows the unique datasets. The dataset page shows more informations, and the analysis results of this dataset. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen |
GSE131984_Pac | SUM159 cell line | Cell line | Breast cancer | triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel |
GSE163836 | FCIBC02 cell line | Cell line | Breast cancer | inflammatory breast cancer | Chemotherapy | paclitaxel |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel |
GSE138267 | CDX | Tumor tissue | Lung cancer | SCLC | Chemotherapy | NA |
GSE186960 | Panc1 cell line | Cell line | Pancreatic cancer | PDAC | Chemotherapy | gemcitabine |
GSE140440 | DU145 and PCÂ cell lines | Cell line | Prostate cancer | prostate cancer | Chemotherapy | docetaxel |
GSE153697 | patients | Bone marrow aspirate | Acute lymphoblastic leukemia | relapsed B-ALL | Immunotherapy | anti-CD19 CAR-T |
GSE197268_Axi-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | large B-ALL | Immunotherapy | axi-cel (CAR-T) |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | large B-ALL | Immunotherapy | tisa-cel (CAR-T) |
GSE169246_PacAteBlood | patients | Peripheral blood mononuclear cells | Breast cancer | advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel |
GSE150930 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | MALT lymphoma | Immunotherapy | rituximab + cyclophosphamide + fludarabine |
GSE212217 | patients | Peripheral blood mononuclear cells | Endometrial cancer | epigenetic MMRd endometrial carcinoma | Immunotherapy | pembrolizumab |
PMID34715028 | patients | Tumor tissue | Kidney cancer | clear cell renal cell carcinoma (ccRCC) | Immunotherapy | nivolumab |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative NSCLC | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) |
GSE207422_Tor | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative NSCLC | Immunotherapy | toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine) |
GSE164237 | patients | Peripheral blood mononuclear cells | Melanoma | advanced stages of melanoma | Immunotherapy | pembrolizumab |
GSE164551 | patients | Bone marrow aspirate | Multiple myeloma | refractory MM | Immunotherapy | CAR-T |
GSE158457 | PDX cells | Cell line | Acute lymphoblastic leukemia | T-ALL | Targeted therapy | dasatinib |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | refractory AML | Targeted therapy | ficlatuzumab |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | primary FLT3-ITD-mutated AML | Targeted therapy | gilteritinib |
GSE104987 | MCF7 cell line | Cell line | Breast cancer | ER+ breast cancer | Targeted therapy | KDM5-C70 |
GSE131984_JQ1 | SUM159 cell line | Cell line | Breast cancer | triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 |
GSE131984_JQ1Pac | SUM159 cell line | Cell line | Breast cancer | triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + paclitaxel |
GSE131984_JQ1Pal | SUM159 cell line | Cell line | Breast cancer | triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + palbociclib |
GSE131984_Pal | SUM159 cell line | Cell line | Breast cancer | triple-negative breast cancer (TNBC) | Targeted therapy | palbociclib |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | CLL | Targeted therapy | ibrutinib |
GSE152469 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | CLL | Targeted therapy | ibrutinib |
GSE175716 | PDX | Tumor tissue | Liver cancer | advanced hepatocellular carcinoma | Targeted therapy | sorafenib |
GSE139386 | H3122 cell line | Cell line | Lung cancer | EML4-ALK fusion-positive NSCLC | Targeted therapy | ceritinib |
GSE149214 | PC9 cell line | Cell line | Lung cancer | EGFR-mutated NSCLC | Targeted therapy | erlotinib |
GSE108397 | 451Lu cell line | Cell line | Melanoma | melanoma | Targeted therapy | PLX-4720 |
GSE164897_Vem | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib |
GSE164897_VemCob | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + combimetinib |
GSE164897_VemTra | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + trametinib |
GSE161195 | patients | Bone marrow aspirate | Multiple myeloma | refractory MM | Targeted therapy | DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone) |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | refractory MM | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | refractory MM | Targeted therapy | carfilzomib + dexamethasone |
GSE189460 | patients | Bone marrow aspirate | Multiple myeloma | MM | Targeted therapy | bortezomib + melphalan + prednisolone |
GSE115251 | Kelly cell line | Cell line | Neuroblastoma | neuroblastoma | Targeted therapy | TAE684 |
GSE168668 | LNCaP cell line | Cell line | Prostate cancer | prostate cancer | Targeted therapy | enzalutamide |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |